Key Highlights:
- Axsome Therapeutics reports a stellar 62% revenue surge in Q1 2025.
- FDA approval of Symbravo and future drug submissions poised to bolster growth.
- Wall Street forecasts suggest a significant upside, with a "Strong Buy" consensus.
Axsome Therapeutics Inc. (AXSM, Financial) has delivered impressive financial results in the first quarter of 2025, marked by a substantial 62% revenue increase. This growth has been fueled largely by the success of Auvelity, contributing a notable $96.2 million. Furthermore, the company's strategic advancements include the FDA approval of Symbravo and plans to submit new drug applications for AXS-14 and AXS-05, aimed at treating fibromyalgia and Alzheimer's agitation, respectively.
Wall Street Analysts' Projections
According to the average one-year price targets from 17 analysts, Axsome Therapeutics Inc. (AXSM, Financial) is projected to reach a price of $176.76. Projections range from a high of $210.00 to a low of $143.00. This average suggests a potential upside of 50.35% from its current price of $117.57. Investors can explore more intricate details and estimates on the Axsome Therapeutics Inc. Forecast page.
Moreover, the consensus from 18 brokerage firms positions Axsome Therapeutics Inc. (AXSM, Financial) with an average brokerage recommendation of 1.7, signaling an "Outperform" status. This rating utilizes a scale where 1 indicates a Strong Buy and 5 indicates a Sell, highlighting strong market confidence in the stock's performance.
Valuation Insights: GF Value
According to GuruFocus estimates, the GF Value projects that Axsome Therapeutics Inc. (AXSM, Financial) is valued at $262.18 within the coming year. This valuation indicates a potential upside of 123% from its current trading price of $117.57. The GF Value derives from historical trading multiples, past growth trends, and future business performance estimates, painting a promising picture for the stock. Detailed valuation data can be found on the Axsome Therapeutics Inc. Summary page.
